治疗遗传性血管性水肿新药艾替班特概述

Overview of Icatibant,a New Drug against Hereditary Angioedema

艾替班特和缓激肽结构类似,与其竞争性地结合缓激肽B2受体,具有良好的药动学特性,对急性发作期遗传性血管性水肿(HAE)的患者疗效佳。同时在发病的第一时间内,患者可以安全地自我治疗。目前的文献报道提示,艾替班特治疗获得性血管性水肿(AAE)的效果与治疗HAE一样安全、有效,或许将来艾替班特也可用于AAE的治疗。

Objective：To get knowledge of the latest development of icatibant,a drug against hereditary angioedema （HAE）.Methods：Many literatures on icatibant were selected from home and abroad.Results ＆ Conclusion：Icatibant is structurally similar to bradykinin and acts as a potent,selective and competitive antagonist of bradykinin type 2 receptor,it also has good pharmacokinetic profile,therefore,it is a good drug against acute episodes of HAE.At the same time,patients can cure HAE by self-administrating icatibant during an acute attack.From the epidemic factor and treatment instances,Icatibant is a safe and effective drug against acquired angioedema（AAE）.Therefore,it will be approved for the treatment of AAE in the future.